Corina Dutcus, SVP, oncology global clinical development lead, Eisai, highlights how long-term LEAP-002 data provides critical reassurance around Lenvima’s durability and safety in treating ...

Endometrial Cancer is a type of cancer that begins in the lining of the uterus, most commonly affecting postmenopausal women. Rising prevalence due to increasing obesity rates and aging population, ...

Corina Dutcus, SVP, oncology global clinical development lead, Eisai, highlights how consistent survival data from the LEAP-002 study reaffirms lenvatinib’s value in first-line treatment of ...

Japanese drugmaker Eisai today revealed that it has launched its Urece (dotinurad) in China as a treatment for gout. Urece ...

Eisai Pharma is set to establish a new Global Capability Center (GCC) in Visakhapatnam, aiming to boost its digital ...

NICE said it made every effort to support reimbursement for Kisunla and Leqembi, but found the medicines are “not good value for money”.

BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that the drug discovery research for lecanemab (product ...

Eisai Pharma, a noted human health care pharmaceutical company with a global presence, announced its plans to establish a new ...

To gain a better insight into Eisai’s current pipeline, its disease areas of importance and what Eisai are conducting beyond therapy development to tackle diseases we spoke with Gary Hendler.

The Bioindustry Award, now marking its 9th year, recognizes achievements that have significantly contributed to the development of the bioindustry or are expected to contribute to its future growth.

Visakhapatnam: Eisai Pharma, a noted human health care pharmaceutical company, announced its plans to establish a new global ...

Premier Doug Ford called the expansion of Eisai Inc. in Mississauga “a major milestone in strengthening our plan to build ...